Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017, Article ID 5831682, 7 pages
https://doi.org/10.1155/2017/5831682
Research Article

Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa

1University Eye Hospital, Hanover Medical School, Hanover, Germany
2Eye Center, University Hospital Freiburg, Freiburg, Germany

Correspondence should be addressed to Amelie Pielen; ed.revonnah-hm@eilema.neleip

Received 13 April 2017; Accepted 28 June 2017; Published 30 July 2017

Academic Editor: Michael J. Koss

Copyright © 2017 Amelie Pielen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Pielen, N. Feltgen, C. Isserstedt, J. Callizo, B. Junker, and C. Schmucker, “Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review,” PloS One, vol. 8, no. 10, article e78538, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Braithwaite, A. A. Nanji, K. Lindsley, and P. B. Greenberg, “Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion,” Cochrane Database of Systematic Reviews, no. 5, article CD007325, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. A. R. Berger, A. F. Cruess, F. Altomare et al., “Optimal treatment of retinal vein occlusion: Canadian expert consensus,” Ophthalmologica Journal International Ophtalmologie International Journal Ophthalmology Zeitschrift Für Augenheilkunde, vol. 234, pp. 6–25, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. P. A. Campochiaro, J. S. Heier, L. Feiner et al., “Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study,” Ophthalmology, vol. 117, pp. 1102.e1–1112.e1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Brown, P. A. Campochiaro, R. P. Singh et al., “Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study,” Ophthalmology, vol. 117, pp. 1124.e1–1133.e1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. D. M. Brown, P. A. Campochiaro, R. B. Bhisitkul et al., “Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study,” Ophthalmology, vol. 118, pp. 1594–1602, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. P. A. Campochiaro, D. M. Brown, C. C. Awh et al., “Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study,” Ophthalmology, vol. 118, pp. 2041–2049, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. F. G. Holz, J. Roider, Y. Ogura et al., “VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study,” The British Journal of Ophthalmology, vol. 97, pp. 278–284, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. J. F. Korobelnik, F. G. Holz, J. Roider et al., “Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study,” Ophthalmology, vol. 121, pp. 202–208, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Ogura, J. Roider, J. F. Korobelnik et al., “Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study,” American Journal of Ophthalmology, vol. 158, no. 5, pp. 1032–1038, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Boyer, J. Heier, D. M. Brown et al., “Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study,” Ophthalmology, vol. 119, pp. 1024–1032, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. D. M. Brown, J. S. Heier, W. L. Clark et al., “Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study,” American Journal of Ophthalmology, vol. 155, pp. 429.e7–437.e7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. P. A. Campochiaro, W. L. Clark, D. S. Boyer et al., “Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study,” Ophthalmology, vol. 122, pp. 538–544, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. D. L. Epstein, P. V. Algvere, G. von Wendt, S. Seregard, and A. Kvanta, “Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study,” Ophthalmology, vol. 119, pp. 1184–1189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. D. L. Epstein, P. V. Algvere, G. von Wendt, S. Seregard, and A. Kvanta, “Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study,” Ophthalmology, vol. 119, pp. 2587–2591, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Haller, F. Bandello, R. Belfort et al., “Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion,” Ophthalmology, vol. 117, pp. 1134.e3–1146.e3, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. J. A. Haller, F. Bandello, R. Belfort et al., “Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results,” Ophthalmology, vol. 118, pp. 2453–2460, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. Germany Ophthalmology Society and Retina Society, “Professional Asociation of German Ophthalmologists. [statement of the German Ophthalmology Society, the Retina Society and the Professional Association of German Ophthalmologists for the treatment of macular edema in retinal vein occlusion: therapeutic strategies],” Ophthalmol Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, vol. 109, pp. 818–831, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. “Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion-full text view-ClinicalTrials.gov,” October 2016, https://clinicaltrials.gov/ct2/show/NCT01427751?term=NCT01427751&rank=1.
  20. L. O. Hattenbach, N. Feltgen, T. Bertelmann et al., “Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B),” Acta Ophthalmologica, 2017. View at Publisher · View at Google Scholar
  21. H. Hoerauf, N. Feltgen, C. Weiss et al., “Clinical efficacy and safety of Ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): a European label study,” American Journal of Ophthalmology, vol. 169, pp. 258–267, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Kim, D. H. Lee, S. H. Byeon, H. J. Koh, S. S. Kim, and S. C. Lee, “Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion,” The British Journal of Ophthalmology, vol. 99, pp. 1271–1276, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Chiquet, C. Dupuy, A. M. Bron et al., “Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study,” Graefes Archive Clinical and Experimental Ophthalmology Albrecht von Graefes Archiv Klinische Experimentelle Ophthalmologie, vol. 253, pp. 2095–2102, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Bajor, A. Pielen, and L. Danzmann, “Retinal vein occlusion-which treatment when?” Klinische Monatsblätter für Augenheilkunde, 2017. View at Publisher · View at Google Scholar
  25. N. Feltgen and A. Pielen, “Retinal vein occlusion: therapy of retinal vein occlusion,” Ophthalmology Zeitchrift Deutschen Ophthalmologischen Gesellschaft, vol. 112, pp. 695–704, 2015, quiz 705–706. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Coscas, A. Loewenstein, A. Augustin et al., “Management of retinal vein occlusion—consensus document,” Ophthalmologica Journal International Ophtalmologie International Journal Ophthalmology Zeitschrift Für Augenheilkunde, vol. 226, pp. 4–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. J. S. Pulido, C. J. Flaxel, R. A. Adelman, L. Hyman, J. C. Folk, and T. W. Olsen, “Retinal vein occlusions preferred practice pattern(®) guidelines,” Ophthalmology, vol. 123, pp. 182–208, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Ehlken, S. Jungmann, D. Böhringer, H. T. Agostini, B. Junker, and A. Pielen, “Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD,” Eye London England, vol. 28, pp. 538–545, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Abri Aghdam, F. Seidensticker, A. Pielen, C. Framme, and B. Junker, “The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography,” Lasers in Surgery and Medicine, vol. 48, pp. 668–677, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Sharareh, R. Gallemore, M. Taban, S. Onishi, and J. Wallsh, “Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion,” Retina Philadelphia PA, vol. 33, pp. 1227–1231, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Chiquet, A. M. Bron, M. Straub et al., “Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up,” Ophthalmic Research, vol. 55, pp. 152–158, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. W. J. Mayer, M. Remy, A. Wolf et al., “Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema,” Ophthalmologica Journal International Ophtalmologie International Journal Ophthalmology Zeitschrift Für Augenheilkunde, vol. 228, pp. 110–116, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. P. A. Campochiaro, R. Sophie, J. Pearlman et al., “Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study,” Ophthalmology, vol. 121, pp. 209–219, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Yamada, A. Nishida, M. Shimozono et al., “Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion,” Japanese Journal of Ophthalmology, vol. 59, pp. 389–393, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Narayanan, B. Panchal, T. Das, J. Chhablani, S. Jalali, and M. H. Ali, “A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report no. 1,” The British Journal of Ophthalmology, vol. 99, pp. 954–959, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. “Study of comparative treatments for retinal vein occlusion 2 (SCORE2) - full text View-ClinicalTrials.gov,” October 2016, https://clinicaltrials.gov/ct2/show/NCT01969708?term=aflibercept+retinal+vein+occlusion&rank=3.